(Reuters) -The U.S. Food and Drug Administration on Friday warned against the use of compounded drugs, including versions of popular weight-loss treatments, made by a California-based facility over concerns that they could be contaminated. The facility, Fullerton Wellness, makes compounded versions of Novo Nordisk’s and Eli Lilly’s weight-loss drugs, among others. It distributes them to […]
Health
US FDA warns against California facility making compounded weight-loss drugs
Audio By Carbonatix
(Reuters) -The U.S. Food and Drug Administration on Friday warned against the use of compounded drugs, including versions of popular weight-loss treatments, made by a California-based facility over concerns that they could be contaminated.
The facility, Fullerton Wellness, makes compounded versions of Novo Nordisk’s and Eli Lilly’s weight-loss drugs, among others. It distributes them to patients by medical offices and clinics.
A tight supply of Lilly’s Mounjaro and Novo Nordisk’s Wegovy has fueled demand for compounding facilities’ own versions of the medicines, which are cheaper. But the FDA has previously warned of dosing risks related to some compounded drugs.
The Fullerton Wellness facility used non-sterile ingredients to make these injectable drugs without sterilization procedures, potentially creating health risks, according to the FDA.
Reuters could not immediately reach Fullerton Wellness for comment.
(Reporting by Sneha S K in Bengaluru; editing by Alan Barona)